Human NRGN blocking peptide

The study was conducted in 2012 and 2013 at three locations in North Central and Western Montana (total of 6 site-years) to evaluate the relative efficacy of three liquid nitrogen (N) fertilizer sources, urea ammonium nitrate (UAN, 32-0-0), liquid urea (LU, 21-0-0), and High NRGN (HNRGN, 27-0-0-1S), in spring wheat (Triticum aestivum L.). In addition to at-seeding urea application at 90 kg Nh a(-1) to all treatments (except for the unfertilized check plot), the liquid fertilizers were applied utilizing an all-terrain vehicle-(ATV-) mounted stream-bar equipped sprayer at a rate of 45 kg N ha(-1) at Feekes 5 growth stage (early tillering). Three dilution ratios of fertilizer to water were accessed: 100/0 (undiluted), 66/33, and 33/66. The effects of N source and the dilution ratio (fertilizer/water) on N uptake (NUp), N use efficiency (NUE), spring wheat grain yield (GY), grain protein (GP) content, and protein yield (PY) were assessed. The dilution ratios had no effect on GY, GP, PY, NUp, and NUE at any of the site-years in this study. Taking into account agronomic and economic factors, LUcan be recommended as the most suitable liquidNfertilizer source for spring wheat cropping systems of the Northern Great Plains.

Objective: To determine whether serum neurogranin (NRGN), glial fibrillary acidic protein (GFAP), and calcium-binding protein S100 beta (S100B) levels are associated with traumatic intracranial lesions compared to computed tomography (CT) findings of patients with mild traumatic brain injury (mTBI). Patients and Methods: The cross-sectional study cohort included 48 patients who were admitted to the Emergency Department with a complaint of mTBI, a Glasgow Coma Scale score of 14-15, and at least one symptom of head trauma (i.e., post-traumatic amnesia, nausea or vomiting, post-traumatic seizures, persistent headache, and transient loss of consciousness). Blood samples and CT scans were obtained for all patients within 4 h of injury. Age-matched patients without intracranial traumatic pathology (CT-) were recruited as a control group. Blood samples were measured for NRGN, GFAP, and S100B levels. Results: Of 48 patients, 24 were CT + and had significantly higher serum NRGN (5.79 vs. 2.95 ng/mL), GFAP (0.59 vs.0.36 ng/mL), and S100B (1.72 vs.0.73 mu g/L) levels than those who were CT- (p = 0.001, p = 0.026, and p < 0.001, respectively). ROC curves showed that NRGN, GFAP, and S100B levels were sufficient to distinguish traumatic brain injury in patients with mTBI. At the cut-off value for NRGN of 1.87 ng/mL, sensivity was 83.3%, and specificity was 58.3%. At the cut-off value for GFAP of 0.23 ng/mL, sensivity was 75% and specificity was 62.5%. The optimal cut-off value for S100B was 0.47 mu g/L (95.8% sensitivity and 62.5% specificity). Conclusion: This is the first study to evaluate NRGN in human serum after mTBI. We confirmed that NRGN levels were significantly higher in CT + patients than CT- patients in the mTBI patient population. Future studies of larger populations and different age groups (especially pediatric) can help reduce the number of CT scans as a reliable and noninvasive diagnostic tool for evaluating NRGN protein levels in mTBI patients with a low probability of intracranial lesions.